Fingerprint
Dive into the research topics of '3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma
Chor Sang Chim, Shaji Kumar, Vincent Kai Chung Wong, Cheong Ngai, Yok Lam Kwong
Research output: Contribution to journal › Article › peer-review